A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Advanced Solid Tumors|Cowden Syndrome
Interventions: DRUG: BEZ235
Sponsor: Novartis Pharmaceuticals